门诊儿科患者通过鼻腔给予右美托咪定的药代动力学及镇静作用研究

2019-08-31 anesthGH 罂粟花

我们的目的是研究通过鼻腔内给予右美托咪定作为小儿磁共振检查镇静剂的药代动力学和镇静作用。

背景与目的

我们的目的是研究通过鼻腔内给予右美托咪定作为小儿磁共振检查镇静剂的药代动力学和镇静作用。

方  法

这是一项开放性单周期研究,没有随机分组。本临床试验包括5个月至11岁的儿童患者,他们计划进行MRI检查,并接受右美托咪定作为术前治疗。在MRI前约1小时内单次滴鼻2-3ug·kg右美托咪定。在4小时内采集5或6个静脉血样本进行右美托咪定浓度分析。用Comfort-B 评分监测镇静,并记录生命体征。采用非室模型拟合药代动力学参数计算变量,并比较3个年龄组(1-24个月,24-6岁,6-11岁以上)的药代动力学变量。

结 果

我们评估了187例连续患者的可行性,其中132例被排除。纳入其余55例患者,其中5例在分析前被排除。平均(标准偏差[SD])剂量校正峰值血浆浓度(Cmax)为0.011升(0.0051),达到峰值浓度(tmax)的中位数(四分位距[IQR])时间为37分钟(30-45)分钟)。Cmax与年龄呈负相关(r = -0.58; 95%置信区间[CI],-0.74至-0.37; P <.001),但与tmax无关(r = -0.14; 95%CI,0.14- 0.39; P = .35)。浓度 - 时间曲线下的剂量校正面积与年龄呈负相关(r = -0.53; 95%CI,0.70至-0.29; P <.001)。Comfort-B镇静评分的中位数(IQR)最大降低为8(6-9),在给药后45分钟(40-48分钟)达到。心率中位数(IQR)比基础值降低15%(9%-23%)。

结 论

右美托咪定在给药后吸收相对较快,对小儿患者具有临床意义,但其镇静作用持续时间较短。

原始出处:

Panu Uusalo, MD, Samuel Guillaume,et al. Pharmacokinetics and Sedative Effects of Intranasal Dexmedetomidine in Ambulatory Pediatric Patients.[J] Anesth Analg.2019; 126:186–91.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1670993, encodeId=6e8316e099355, content=<a href='/topic/show?id=0de92811870' target=_blank style='color:#2F92EE;'>#儿科患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28118, encryptionId=0de92811870, topicName=儿科患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9f26811685, createdName=longqijun257, createdTime=Tue Jul 28 21:58:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666739, encodeId=22bd1666e392b, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 03 17:58:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351276, encodeId=e9d813512e656, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 02 07:58:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465858, encodeId=4188146585819, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Mon Sep 02 07:58:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1670993, encodeId=6e8316e099355, content=<a href='/topic/show?id=0de92811870' target=_blank style='color:#2F92EE;'>#儿科患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28118, encryptionId=0de92811870, topicName=儿科患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9f26811685, createdName=longqijun257, createdTime=Tue Jul 28 21:58:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666739, encodeId=22bd1666e392b, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 03 17:58:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351276, encodeId=e9d813512e656, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 02 07:58:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465858, encodeId=4188146585819, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Mon Sep 02 07:58:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
    2019-11-03 fengyqf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1670993, encodeId=6e8316e099355, content=<a href='/topic/show?id=0de92811870' target=_blank style='color:#2F92EE;'>#儿科患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28118, encryptionId=0de92811870, topicName=儿科患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9f26811685, createdName=longqijun257, createdTime=Tue Jul 28 21:58:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666739, encodeId=22bd1666e392b, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 03 17:58:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351276, encodeId=e9d813512e656, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 02 07:58:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465858, encodeId=4188146585819, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Mon Sep 02 07:58:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1670993, encodeId=6e8316e099355, content=<a href='/topic/show?id=0de92811870' target=_blank style='color:#2F92EE;'>#儿科患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28118, encryptionId=0de92811870, topicName=儿科患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9f26811685, createdName=longqijun257, createdTime=Tue Jul 28 21:58:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666739, encodeId=22bd1666e392b, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 03 17:58:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351276, encodeId=e9d813512e656, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 02 07:58:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465858, encodeId=4188146585819, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Mon Sep 02 07:58:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
    2019-09-02 mnda

相关资讯

BMC Anesthesiol:右美托咪定联合舒芬太尼与舒芬太尼单独使用用于术后静脉病人自控镇痛的比较:一项系统性回顾和随机对照试验的meta分析

以往的研究表明,右美托咪定能提高术后镇痛的质量。在本研究中,我们对随机对照试验进行了Meta分析,以量化右美托咪定作为舒芬太尼佐剂用于术后病人自控镇痛(PCA)的效果。

BJA:右美托咪定镇静状态下,儿童认知记忆评估的可行性

右美托咪定对儿童记忆的影响尚未有前瞻性的研究,本研究主要确定是否能在儿童患者中获取质量可靠的数据用以建立记忆和镇静反应间的模型。采用标准的视觉图片命名任务来评估当镇静程度逐渐加深时的记忆。研究的次要观察指标建立时间与右美托咪定镇静效应(丧失语言反应)和存在认知记忆的回归模型。

右美托咪定致呼吸暂停1例

本例患者为本院2016年10月11日所收治,女,38岁,体重55kg,美国麻醉医师协会(ASA)I级,因CINⅢ、宫颈HPV感染拟在腰硬联合麻醉下行宫颈锥形切除术。既往体健,未合并其他疾病,否认传染病史,否认有其他药物过敏史。术前体格检查:体温(T)36.8℃,HR78次/min,RR18次/min,BP122/76mmHg,心、肺、腹未见明显异常。辅助检查:血常规、肝肾功能及电解质正常,心电图正

BMC Anesthesiol:右美托咪定通过激活PI3K/AKT/MTOR途径抑制七氟醚麻醉诱导的神经炎症反应

七氟醚是一种吸入性全身麻醉剂,已经成为外科中应用最广泛的吸入性麻醉剂之一。然而,先前的研究已经发现七氟醚麻醉能引起炎症反应,导致二次伤害。右美托咪定(DEX)是一种高选择性α肾上腺素受体激动剂,作为一种麻醉辅助药广泛应用于临床。在这项研究中,我们研究了DEX是否能够抑制七氟醚引起的神经炎症反应。

NEJM:右美托咪定单药用于危重病人的早期镇静

在ICU接受机械通气的患者中,早期接受右旋美托咪定镇静剂的患者在90天时的死亡率与常规护理组相似,需要补充镇静剂才能达到规定的镇静剂水平。右美托咪啶组报告的不良事件多于常规护理组

Anaesthesia:瑞芬太尼与右美托咪定用于术中镇痛的比较:系统回顾与meta分析

术中瑞芬太尼的使用与术后镇痛需求及阿片类药物使用量增加有关。右美托咪定具有可取代瑞芬太尼用于术中全身麻醉的特点,但现有文献报道的结果之间相互矛盾。我们进行这项meta分析,旨在探讨是否使用包括右美托咪定在内的全身麻醉会比使用包括瑞芬太尼在内的全身麻醉所引起的术后疼痛更少。